Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06029257 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 29, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Jul 2025 to Mar 2026v3
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 2023 to Nov 14, 2023v2 Show 1 more changeShow less
    • Start date changed from estimate of Sep 2023 to Nov 14, 2023
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Almirall, S.A.
15 trials monitored
See all monitored trials
Psoriasis
420 trials monitored
See 17 trials at risk
The main aim of this study is to check the safety and effectiveness of tildrakizumab regarding the alleviation of symptoms in the genital area after administration according to the summary of product characteristics (SmPC) and to access overall treatment safety and quality of life assessed on multiple scales.
Trial Details
NCT Number NCT06029257
Lead Sponsor Almirall, S.A.
Conditions Genital Psoriasis
Enrollment 110 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov